420
Participants
Start Date
November 2, 2025
Primary Completion Date
June 28, 2030
Study Completion Date
July 29, 2033
AZD0486
Bispecific monoclonal IgG4 antibody
R-mini-CHOP
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
Research Site, Brussels
Research Site, Antwerp
Research Site, Melbourne
Research Site, Leuven
Research Site, Seoul
Research Site, Yvoir
Research Site, Nedlands
Research Site, Roeselare
Research Site, Ghent
Research Site, Shanghai
Research Site, Nanchang
Research Site, Hong Kong
Research Site, Porto Alegre
Research Site, São Paulo
Research Site, Calgary
Research Site, Ottawa
Research Site, Shatin
Research Site, Bunkyō City
Research Site, Kōtoku
Research Site, Osaka
Research Site, Sunto-gun
Research Site, Yamagata
Research Site, Yokohama
Research Site, Seoul
Lead Sponsor
AstraZeneca
INDUSTRY